2022
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
Chen B, Hu J, Hu X, Chen H, Bao R, Zhou Y, Ye Y, Zhan M, Cai W, Li H, Li HB. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nature Communications 2022, 13: 2059. PMID: 35440133, PMCID: PMC9018773, DOI: 10.1038/s41467-022-29754-y.Peer-Reviewed Original ResearchConceptsPD-L1 expressionTumor immune evasionImmune evasionReduced PD-L1 expressionDeath ligand 1Tumor-killing activityT cellsTherapeutic targetTumor growthCancer cellsCRISPR/Cas9 screeningLigand 1Cell homeostasisKinase 2ExpressionEvasionCD8ImmunotherapyCellsIFNγDysfunctionRBP dysfunctionTumorsCancer
2021
Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation
Tong J, Wang X, Liu Y, Ren X, Wang A, Chen Z, Yao J, Mao K, Liu T, Meng FL, Pan W, Zou Q, Liu J, Zhou Y, Xia Q, Flavell RA, Zhu S, Li HB. Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation. Science Advances 2021, 7: eabd4742. PMID: 33910903, PMCID: PMC8081357, DOI: 10.1126/sciadv.abd4742.Peer-Reviewed Original ResearchConceptsMacrophage activationPotential cancer immunotherapy targetInnate immune cellsFaster tumor growthTNF-α productionInnate immune responseCancer immunotherapy targetCre miceImmune cellsImmunotherapy targetImmune responseLPS stimulationTumor growthBacterial infectionsTop candidate genesDeficient macrophagesMultiple cellular responsesMETTL3 deficiencyActivationUnknown roleMETTL3Negative regulatorBinding proteinCellular responsesRNA binding protein